Inhaled Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-IgE agents, Anti-IL-5 agents, Anti-IL-5 receptor agents, Anti-IL-4/IL-13 pathway agents, Anti-IL-4/IL-13 pathway agents, Anti-TSLP agents, Anti-IL-33 agents, & Others), By Disease Indication (Asthma, COPD, Allergic Rhinitis/Upper Airway Allergy, Chronic Rhinosinusitis, Respiratory Viral Infections, & Others), By Device Type (Intranasal Spray/Drops, Dry Powder Inhaler, Metered Dose Inhaler (MDI / pMDI), & Others), By Age Group (Pediatric and Adults), By Distribution Channel, and Regional Forecast, 2026-2034

Last Updated: March 20, 2026 | Format: PDF | Report ID: FBI115786

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 14.36% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Disease Indication, Device Type, Age Group, Distribution Channel, and Region
By Drug Class	Anti-IgE agents Anti-IL-5 agents Anti-IL-5 receptor agents Anti-IL-4/IL-13 pathway agents Anti-TSLP agents Anti-IL-33 agents Anti-GM-CSF agents Anti-TNF agents Cytokine/Chemokine Pathway Inhibitors Others
By Disease Indication	Asthma COPD Allergic Rhinitis/Upper Airway Allergy Chronic Rhinosinusitis Respiratory Viral Infections Cystic Fibrosis Bronchiectasis/Chronic Airway Infection Pulmonary Fibrosis/ILDs Others
By Device Type	Intranasal Spray/Drops Dry Powder Inhaler (DPI) Metered Dose Inhaler (MDI / pMDI) Nebulized/Aerosolized Delivery Soft Mist Inhaler (SMI) Others
By Age Group	Pediatric Adults
By Distribution Channel	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies
By Region	North America (By Drug Class, Disease Indication, Device Type, Age Group, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Disease Indication, Device Type, Age Group, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Disease Indication, Device Type, Age Group, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Disease Indication, Device Type, Age Group, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Disease Indication, Device Type, Age Group, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa